[PRNewswire] Insilico Medicine Signs Strategic Research Collaboration with
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"We are very happy to collaborate with Sanofi, a company with a clear strategy in AI-powered drug discovery," said Alex Zhavoronkov, PhD, CEO and founder of Insilico Medicine. "This close collaboration will allow Sanofi to immediately gain the capabilities of one of the top AI startups in addition to enriching their drug discovery pipeline."
"We are thrilled to collaborate with Sanofi. Leveraging Sanofi's strong drug research and development expertise and Insilico's powerful AI platform, we believe we can accelerate novel therapeutics discovery to address diseases with unmet medical needs," said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. "Together we will use cutting-edge AI technologies to make significant breakthroughs in drug R&D."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Sanofi worth up to $1.2 Billion
-- Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single- to low double-digit royalties.
(New York, Nov. 8, 2022 PRNewswire=연합뉴스) Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi. Under the terms of the agreement, the collaboration will leverage Insilico Medicine's AI platform, Pharma.AI, to advance drug development candidates for up to six new targets.
"We look forward to working with Insilico Medicine, a demonstrated leader in AI-powered drug discovery," said Changchun Xiao, Head of China Research at Sanofi. "This collaboration will leverage our complementary capabilities, as well as the co-location of our scientific teams, to boost the drug discovery efforts of the Sanofi Institute for Biomedical Research (SIBR), Sanofi's R&D center in China."
Under the terms of the agreement, Sanofi will pay Insilico Medicine a total of up to $21.5 million covering the upfront and target nomination fees to benefit from Insilico's end-to-end Pharma.AI platform and gain access to a team of interdisciplinary drug discovery scientists to identify, synthesize, and advance high-quality lead therapeutic compounds up to development candidate stage. Additional payments will be made if key research, development, and sales milestones are met, and could total more than $1.2 billion. The collaboration also establishes mid-single to up to low double-digit tiered royalties for any products developed.
"We are very happy to collaborate with Sanofi, a company with a clear strategy in AI-powered drug discovery," said Alex Zhavoronkov, PhD, CEO and founder of Insilico Medicine. "This close collaboration will allow Sanofi to immediately gain the capabilities of one of the top AI startups in addition to enriching their drug discovery pipeline."
"We are thrilled to collaborate with Sanofi. Leveraging Sanofi's strong drug research and development expertise and Insilico's powerful AI platform, we believe we can accelerate novel therapeutics discovery to address diseases with unmet medical needs," said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. "Together we will use cutting-edge AI technologies to make significant breakthroughs in drug R&D."
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.
For more information, visit www.insilico.com
For business development inquiries, contact bd@insilicomedicine.com
Source: Insilico Medicine
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 野 "불법 공천개입" 용산 "공천지시한 적 없다"…11월 정국 격랑 | 연합뉴스
- 북한, 美대선 앞두고 ICBM 도발…정부, 새 대북 독자제재 발표 | 연합뉴스
- 우크라, '러 파병' 北장성 3명 공개…"김영복·리창호·신금철"(종합) | 연합뉴스
- 태풍 '콩레이' 비바람 안고 한반도로…정부, 피해 최소화 점검 | 연합뉴스
- 檢, '대북송금' 이화영에 2심도 징역 15년 구형…내달 29일 선고(종합2보) | 연합뉴스
- 고려아연에 칼빼든 금감원…"공개매수 중 유증, 부정거래 소지"(종합2보) | 연합뉴스
- "하늘나라서 행복해야 해"…7세 초등생 친구·주민들 추모 발길(종합) | 연합뉴스
- 월드옥타 '한국상품박람회' 2천400억대 수출 성과…새 역사 썼다 | 연합뉴스
- 체코 "예비조치는 필요시 항상 발령…경쟁사들 입찰조건 수락" | 연합뉴스
- '적과 동침'도 불사…삼성전자, 엔비디아 업고 반전 이룰까 | 연합뉴스